The "therapeutic footprint" of medical, complementary and alternative therapies and a doctor's duty of care
Authors: Craig S Hassed, Vicki Kotsirilos, Marie Pirotta and Avni Sali
Published online: 19 February 2007
To the Editor: Sanderson et al provide an interesting viewpoint about how the community, including medical practitioners, have embraced complementary and alternative medicine (CAM).1
However, if we were reviewing this article for publication, we would ask the authors to:
make a valid distinction between those complementary and alternative therapies promoted as curative versus those considered palliative;
define how they decided which therapies belong to one or other side of the arbitrary CAM boundary;
review and justify the boundaries for the “therapeutic footprint” in a more evidence-based and rigorous way;
locate specific therapies inside the footprint;
locate where chemotherapy lies within the footprint, in light of the recent review showing, for the vast majority of adult malignancies, its marginal survival benefits considering its high costs, both monetary and healthwise;2
emphasise that there are relatively few recorded adverse events for CAM compared with conventional cancer care (Therapeutic Goods Administration Medicine Summary reports 2003, 2004, 2005 — Dr K Mackay, Acting Director, Adverse Drug Reactions Unit, TGA, personal communication); and
vigorously question the marketing of conventional medicines, such as trastuzumab (Herceptin, Roche), to vulnerable patients and an uncritical public when the evidence suggests huge expense and little, if any, survival benefit.3
Perhaps a distinction also needs to be made between CAM therapies, many of which provide proven symptomatic relief, and those lifestyle interventions, such as exercise,4 dietary change,5 and social support, which provide symptomatic relief and may also confer a survival benefit. It does not serve the profession well when many cancer patients and their carers have to go outside the medical system to access information, advice and therapies which they should have easy access to within the system. In fact, we might even question how helpful these arbitrary boundaries are when all that patients and doctors want is to use what works and what is safe.
References
- Sanderson CR, Koczwara B, Currow DC. The "therapeutic footprint" of medical, complementary and alternative therapies and a doctor's duty of care. Med J Aust 2006; 185: 373-376. CBBCGJEF
- Morgan G, Ward R, Barton M. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol (R Coll Radiol) 2004; 16: 549-560. CBBJHBCI
- Murray S. Trastuzumab (Herceptin) and HER2-positive breast cancer. CMAJ 2006; 174: 36-37. i1091801
- Holmes MD, Chen WY, Feskanich D, et al. Physical activity and survival after breast cancer diagnosis. JAMA 2005; 293: 2479-2486. CBBHFABB
- Rock CL, Flatt SW, Natarajan L, et al. Plasma carot-enoids and recurrence-free survival in women with a history of breast cancer. J Clin Oncol 2005; 23: 6631-6638. i1091806
Country revealing the way: evaluating Elder‐governed cultural therapy for Aboriginal and Torres Strait Islander young people with mental health conditions
Alasdair Vance, Janet McGaw, Jo Winther, Naomi Tootell, Herb Patten, Sandra Eades
No silver lining with health misinformation: argyria caused by intentional silver consumption
Luke Collins, Logesh Palanikumar, Stephen Bacchi
Hyperkalaemic cardiac arrest due to cream of tartar ingestion
Daniel Yee Lee Ng, Laksmi Govindasamy, Andrew Hughes, Hwee Min Lee
From talk to action: Indigenous Reference Groups drive practice change in kidney transplantation care
Kelli J Owen, Katie Cundale, Jaquelyne T Hughes, Stephen P McDonald, Matilda D'Antoine, Shilpanjali Jesudason
The not‐so‐natural herb: a case of exogenous Cushing syndrome
Yi‐An Pan, David Roberts, Yi‐An Pan, David Roberts
Lead poisoning outbreak from consumption of contaminated Ayurvedic medication
Mark J Ferson, Sinead Flanigan, Toni Cains